Profile | GDS2987 / GI_38371736-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 26.1 | 54 |
GSM215253 | HMVEC_vehicle_rep3 | 9.5 | 31 |
GSM215254 | HMVEC_atorvastatin_rep1 | 14.3 | 36 |
GSM215282 | HMVEC_atorvastatin_rep3 | 14.3 | 33 |
GSM215344 | HMVEC_atorvastatin_rep2 | 14.3 | 34 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 12.7 | 25 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 21.1 | 40 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 8.5 | 14 |
GSM215294 | HMVEC_SLx2119_rep1 | 7.1 | 26 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 34.3 | 50 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 9.8 | 16 |
GSM215310 | PASMC_vehicle_rep3 | 2.4 | 4 |
GSM215311 | PASMC_atorvastatin_rep1 | 6.6 | 12 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 17.7 | 26 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 22.3 | 40 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 0.3 | 0 |
GSM215327 | PASMC_SLx2119_rep1 | 36.1 | 53 |
GSM215328 | PASMC_SLx2119_rep2 | 38.7 | 56 |
GSM215329 | PASMC_SLx2119_rep3 | 14.8 | 28 |
GSM215330 | Fibroblasts_vehicle_rep1 | 20.7 | 43 |
GSM215331 | Fibroblasts_vehicle_rep2 | 12 | 33 |
GSM215332 | Fibroblasts_vehicle_rep3 | 34 | 64 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 0.7 | 2 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 11.9 | 37 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 13.8 | 41 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 13.8 | 37 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 3.7 | 11 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 11.4 | 28 |